Clinical Trial Update: A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. [Phase 3]

View source ↗

Summary

This document reports the completion and posting of Phase III results for ligelizumab in adolescents and adults with chronic spontaneous urticaria inadequately …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Ligelizumab (ligelizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2024-03-25